BillionToOne Announces Global Collaboration to Provide its UNITY Fetal Antigen™ Clinical Trial Assay in Johnson & Johnson Phase 3 Clinical Trial of Nipocalimab in Hemolytic Disease of the Fetus and Newborn

The UNITY Fetal Antigen Clinical Trial Assay has received Investigational Device Exemption (IDE) as part of this initiative MENLO PARK, Calif., Dec. 12, 2023 /PRNewswire/ — BillionToOne (BTO), a molecular diagnostics company with a mission to create powerful and accurate tests that are…

Click here to view original post

Advertisement — Advertise with Biotech Networks